## Mingli Peng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7068027/publications.pdf Version: 2024-02-01



MINCH PENC

#	Article	IF	CITATIONS
1	Safety and antibody response to inactivated COVIDâ€19 vaccine in patients with chronic hepatitis B virus infection. Liver International, 2022, 42, 1287-1296.	3.9	36
2	Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence. Chinese Medicine, 2022, 17, 23.	4.0	5
3	Curc-mPEG454, a PEGylated curcumin derivative, as a multi-target anti-fibrotic prodrug. International Immunopharmacology, 2021, 101, 108166.	3.8	4
4	The Characteristics of Natural Killer Cells and T Cells Vary With the Natural History of Chronic Hepatitis B in Children. Frontiers in Pediatrics, 2021, 9, 736023.	1.9	1
5	Identification of key genes, pathways and potential therapeutic agents for liver fibrosis using an integrated bioinformatics analysis. PeerJ, 2019, 7, e6645.	2.0	31
6	Curc-mPEG454, a PEGylated Curcumin Derivative, Improves Anti-inflammatory and Antioxidant Activities: a Comparative Study. Inflammation, 2018, 41, 579-594.	3.8	11
7	PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR- <i>γ</i> /CD36 Pathway. BioMed Research International, 2017, 2017, 1-11.	1.9	32
8	Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0180725.	2.5	48
9	Functional dichotomy of Vδ2 γδT cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Scientific Reports, 2016, 6, 26296.	3.3	24
10	Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70. Vaccine, 2006, 24, 887-896.	3.8	25